beta
Trial Radar AI
Clinical Trial NCT07414056 for Acute Respiratory Distress Syndrome (ARDS) is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation 60 Pediatric

Recruiting
Clinical Trial NCT07414056 is an observational study for Acute Respiratory Distress Syndrome (ARDS) that is recruiting. It started on November 10, 2025 with plans to enroll 60 participants. Led by Ain Shams University, it is expected to complete by November 10, 2027. The latest data from ClinicalTrials.gov was last updated on March 2, 2026.
Brief Summary
The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.
Detailed Description

The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.

  • A prospective observational cohort study will be performed in our burn ICU at Ain Shams University Hospitals. Ethical clearance will be taken from the institutional ethics committee. Written informed consent will be obtained from the patients/...
Show More
Official Title

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

Conditions
Acute Respiratory Distress Syndrome (ARDS)
Other Study IDs
  • FMASU MD313/2025
NCT ID Number
NCT07414056
Start Date (Actual)
2025-11-10
Last Update Posted
2026-03-02
Completion Date (Estimated)
2027-11-10
Enrollment (Estimated)
60
Study Type
Observational
Status
Recruiting
Arms / Interventions
Participant Group/ArmIntervention/Treatment
N/A
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction using the Pediatric Index of Mortality 2 score (PIM2 score).
the predictive value of admission Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction within 30 days in 60 pediatric burn patients using the Pediatric Index of Mortality 2 score (PIM2 score). The PIM2 score outputs a probability of death between 0% and 100%, the higher the score, the higher the motality risk. Low risk: \<5-10% predicted mortality; Moderate risk: 10-20%; High risk: \>20%
Within 30 days
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
optimal cut-off values
optimal cut-off values (Receiver Operating Characteristic curve "ROC") of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction in 60 pediatric burn patients.
30 days
comparison between Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) in clinical aspects using pediatric risk of mortality score (PRISM III score)
Compare predictive performance of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) with established clinical predictors (Total Body Surface Area Percentage "TBSA%", inhalation injury, age in years) in 60 pediatric burn patients using pediatric risk of mortality score (PRISM III score). PRISM III Score Ranges from 0 to \>25. 0-5 means Low risk of mortality, mild critical illness; 6-15 means Moderate risk; significant physiologic instability; 16-25 means High risk; severe multi-organ involvement; \>25 means Extremely high risk; very critical state.
30 days
Dynamic changes of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) using the Pediatric Logistic Organ Dysfunction (PELOD) score to assess severity of burn.
Study the predictive value of the dynamic changes of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for mechanical ventilation need, ventilator days, ICU length of stay in days, and mortality in 60 pediatric burn patients using the Pediatric Logistic Organ Dysfunction (PELOD) score. Maximum score: 33. Higher scores indicate greater severity. Higher PELOD-2 scores and involvement of multiple organ systems correlate with increased risk of mortality. A score \>10 or involvement of \>2 organs indicates significantly elevated risk.
30 days
Participation Assistant
Eligibility Criteria

Eligible Ages
Child
Minimum Age
1 Year
Eligible Sexes
All
  • Age 1-12 years.
  • Patients presenting within 24 hours of burn injury.
  • Patients presenting with severe burns 20-40% of total body surface area (TBSA).
  • Thermal burns or scalds.
  • Both sexes.

  • Patient refusal to participate in the trial.
  • Age <1 & >12 years.
  • Delayed admission >24h post-injury.
  • Patients presenting with burns <20% or >40% of TBSA.
  • Non-thermal burns.
  • Associated medical comorbidities: Chronic liver or kidney diseases, anemia.
  • Preexisting chronic lung disease (e.g., cystic fibrosis, severe bronchopulmonary dysplasia).
  • Inflammatory conditions (e.g., inflammatory bowel disease).
  • Immunocompromised individuals, autoimmune diseases, those undergoing treatment with immunosuppressants, corticosteroids, cytotoxic chemotherapy.
  • Known malignancies, hematologic malignancy or conditions altering WBC/platelets significantly.
  • Previous malnutrition.
  • Immunosuppressive therapy prior to admission (e.g., chronic steroids).
Ain Shams University logoAin Shams University344 active studies to explore
No contact data.
1 Study Locations in 1 Countries
Ain Shams University, Cairo, Egypt
Ahmed Kamal Kamar Kamar, M.B.B.CH., M.Sc., Contact, 00201027733119, [email protected]
Ain Shams University, Contact, [email protected]
Recruiting